{"id":"velcade-thalidomide-dexamethasone","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"},{"rate":"5-20%","effect":"Pyrexia"},{"rate":"5-20%","effect":"Headache"},{"rate":"5-20%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting proteasomes, Velcade disrupts the normal functioning of cells, leading to cell death, particularly in cancer cells. This mechanism is particularly effective in multiple myeloma and mantle cell lymphoma. Additionally, Thalidomide works by inhibiting the production of tumor necrosis factor-alpha (TNF-alpha), a protein that promotes inflammation and tumor growth, while Dexamethasone is a corticosteroid that suppresses the immune system and reduces inflammation.","oneSentence":"Velcade (bortezomib) is a proteasome inhibitor that blocks the action of proteasomes, which are complexes that break down proteins in cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:55.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT00572169","phase":"PHASE3","title":"UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2006-11","conditions":"Multiple Myeloma","enrollment":177},{"nctId":"NCT02461888","phase":"PHASE2","title":"Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":112},{"nctId":"NCT07247097","phase":"PHASE2","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-04-15","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible","enrollment":160},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT03896737","phase":"PHASE2","title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":401},{"nctId":"NCT00871013","phase":"PHASE2","title":"Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2009-03","conditions":"Myeloma","enrollment":160},{"nctId":"NCT00869232","phase":"PHASE2","title":"UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-10","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT00734877","phase":"PHASE3","title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":382},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT02541383","phase":"PHASE3","title":"A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Intergroupe Francophone du Myelome","startDate":"2015-09","conditions":"Multiple Myeloma","enrollment":1085},{"nctId":"NCT01539083","phase":"PHASE3","title":"Velcade (Bortezomib) Consolidation After Transplant","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2012-01-13","conditions":"Multiple Myeloma","enrollment":256},{"nctId":"NCT06284395","phase":"","title":"Two Schemes Response in Multiple Myeloma","status":"RECRUITING","sponsor":"Hospital General de Mexico","startDate":"2023-11-20","conditions":"Response, Acute Phase, Survivorship","enrollment":83},{"nctId":"NCT04352205","phase":"PHASE2","title":"Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure","status":"TERMINATED","sponsor":"Emory University","startDate":"2020-05-07","conditions":"Plasma Cell Myeloma, Renal Failure","enrollment":17},{"nctId":"NCT06457464","phase":"","title":"Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-07-01","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT03759093","phase":"PHASE2, PHASE3","title":"CURATE.AI Optimized Modulation for Multiple Myeloma","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2023-09-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT01242267","phase":"PHASE1, PHASE2","title":"Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2010-05-11","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT05561049","phase":"","title":"Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-10-01","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":120},{"nctId":"NCT01849783","phase":"PHASE2","title":"Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Margarida Magalhaes-Silverman","startDate":"2013-04-04","conditions":"Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease","enrollment":41},{"nctId":"NCT02424851","phase":"PHASE2","title":"Optimising Renal Outcome in Myeloma Renal Failure","status":"COMPLETED","sponsor":"Oxford University Hospitals NHS Trust","startDate":"2014-11","conditions":"Multiple Myeloma, Chronic Kidney Disease","enrollment":31},{"nctId":"NCT00256776","phase":"PHASE3","title":"MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation","status":"TERMINATED","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2005-07","conditions":"Multiple Myeloma","enrollment":269},{"nctId":"NCT00792142","phase":"PHASE2","title":"Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-01-16","conditions":"Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity","enrollment":45},{"nctId":"NCT03393273","phase":"PHASE2","title":"Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-20","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT00124579","phase":"PHASE2","title":"S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2005-08","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT01526694","phase":"PHASE2","title":"Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM","status":"COMPLETED","sponsor":"Azienda Ospedaliera di Bolzano","startDate":"2012-07","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT01554852","phase":"PHASE3","title":"Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":4420},{"nctId":"NCT02559154","phase":"PHASE4","title":"Modified Bortezomib-based Combination Therapy for Multiple Myeloma","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2010-07","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT03402295","phase":"PHASE3","title":"Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation","status":"COMPLETED","sponsor":"Grupo de Estudos Multicentricos em Onco-Hematologia","startDate":"2009-06-15","conditions":"Multiple Myeloma, Effects of Chemotherapy","enrollment":311},{"nctId":"NCT00574080","phase":"PHASE3","title":"UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2006-07","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT03335098","phase":"PHASE2","title":"Study of VTD in Waldenstrom's Macroglobulinemia","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-11-21","conditions":"Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma","enrollment":15},{"nctId":"NCT00081939","phase":"PHASE2","title":"UARK 2003-33, Total Therapy III","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2004-01","conditions":"Multiple Myeloma","enrollment":303},{"nctId":"NCT00670631","phase":"PHASE2","title":"Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment","status":"COMPLETED","sponsor":"Guido Tricot","startDate":"2008-02","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT01548573","phase":"PHASE2","title":"Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment","status":"TERMINATED","sponsor":"University of Iowa","startDate":"2012-05","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT02981199","phase":"NA","title":"Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"Chen Wenming","startDate":"2016-01","conditions":"Microtransplantation, Autologous Stem Cell Transplantation, Multiple Myeloma in Relapse","enrollment":80},{"nctId":"NCT00458705","phase":"PHASE2","title":"Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-11","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":45},{"nctId":"NCT01971658","phase":"PHASE3","title":"Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2013-10","conditions":"Multiple Myeloma","enrollment":358},{"nctId":"NCT00111748","phase":"PHASE3","title":"UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2005-02","conditions":"Multiple Myeloma","enrollment":180},{"nctId":"NCT02145715","phase":"PHASE1, PHASE2","title":"Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma","status":"UNKNOWN","sponsor":"Prof Jamie Cavenagh","startDate":"2013-01","conditions":"Multiple Myeloma","enrollment":54},{"nctId":"NCT00522392","phase":"PHASE3","title":"Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-09","conditions":"Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":48},{"nctId":"NCT00723658","phase":"PHASE2","title":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-09","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT01055301","phase":"PHASE2","title":"S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2011-07","conditions":"Multiple Myeloma, Plasma Cell Myeloma","enrollment":""},{"nctId":"NCT01537861","phase":"EARLY_PHASE1","title":"Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-06","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT00507416","phase":"PHASE3","title":"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2007-06","conditions":"Multiple Myeloma","enrollment":502},{"nctId":"NCT00258245","phase":"PHASE1","title":"Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2005-05","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":5},{"nctId":"NCT01134484","phase":"PHASE3","title":"VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)","status":"UNKNOWN","sponsor":"Michele Cavo","startDate":"2006-05","conditions":"Multiple Myeloma","enrollment":480},{"nctId":"NCT00531453","phase":"PHASE2","title":"A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2007-10","conditions":"Multiple Myeloma","enrollment":98},{"nctId":"NCT01328236","phase":"PHASE2","title":"Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia","status":"UNKNOWN","sponsor":"Clinical Service, China","startDate":"2010-09","conditions":"Plasma Cell Leukemia, Multiple Myeloma","enrollment":20},{"nctId":"NCT01114048","phase":"PHASE2","title":"Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)","status":"UNKNOWN","sponsor":"Chonnam National University Hospital","startDate":"2010-03","conditions":"Multiple Myeloma","enrollment":78},{"nctId":"NCT00652041","phase":"PHASE4","title":"Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2007-01","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT00573391","phase":"PHASE3","title":"Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2006-08","conditions":"Multiple Myeloma","enrollment":5},{"nctId":"NCT00577668","phase":"PHASE2","title":"A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2007-04","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT00602511","phase":"PHASE3","title":"Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma","status":"COMPLETED","sponsor":"Nordic Myeloma Study Group","startDate":"2007-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT01249690","phase":"PHASE4","title":"Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma","status":"UNKNOWN","sponsor":"Second Military Medical University","startDate":"2010-06","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT00083460","phase":"PHASE1","title":"Study of Combination PS-341 and Thalidomide in Multiple Myeloma","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-12","conditions":"Multiple Myeloma","enrollment":86},{"nctId":"NCT00461747","phase":"PHASE3","title":"GEM05 for Patients With Multiple Myeloma Under 65 Years","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-03","conditions":"Multiple Myeloma","enrollment":390},{"nctId":"NCT00910897","phase":"PHASE3","title":"Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)","status":"UNKNOWN","sponsor":"Intergroupe Francophone du Myelome","startDate":"2008-03","conditions":"Multiple Myeloma","enrollment":205},{"nctId":"NCT00438841","phase":"PHASE2","title":"Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma","status":"UNKNOWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-08","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":43},{"nctId":"NCT00320476","phase":"PHASE2","title":"VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates","status":"COMPLETED","sponsor":"Korean Multiple Myeloma Working Party","startDate":"2006-04","conditions":"Multiple Myeloma","enrollment":35},{"nctId":"NCT00378755","phase":"PHASE2","title":"Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM","status":"UNKNOWN","sponsor":"Korean Multiple Myeloma Working Party","startDate":"2006-03","conditions":"Multiple Myeloma","enrollment":62},{"nctId":"NCT00319865","phase":"PHASE2","title":"PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Korean Multiple Myeloma Working Party","startDate":"2005-11","conditions":"Multiple Myeloma","enrollment":47}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Velcade, Thalidomide, Dexamethasone","genericName":"Velcade, Thalidomide, Dexamethasone","companyName":"University of Arkansas","companyId":"university-of-arkansas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Velcade (Bortezomib) is a small molecule used in the treatment of multiple myeloma, specifically in regimens such as the CTD (cyclophosphamide, thalidomide, and dexamethasone) and CCRD (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) regimens. Thalidomide is also used in the treatment of multiple myeloma, often in combination with dexamethasone, as seen in the CTD regimen.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}